Overview
Alterity Therapeutics Ltd (ASX: ATH, formerly Prana Biotechnology) is an Australian biotechnology company focused on developing novel disease-modifying therapies for Parkinson's disease and other neurodegenerative disorders characterized by abnormal protein aggregation. The company's lead programs target alpha-synuclein aggregation, the pathological hallmark of Parkinson's disease and related synucleinopathies, through small molecule inhibitors that prevent the formation of toxic protein oligomers and fibrils [1][2][3].
Founded in 1997 as Prana Biotechnology, the company underwent a strategic transformation and rebranded to Alterity Therapeutics in 2021 to reflect its expanded pipeline focus beyond its original mitochondrial targeting programs. The name "Alterity" reflects the company's mission to alter the course of neurodegenerative disease by targeting the fundamental protein aggregation processes that drive neuronal dysfunction and death [1].
Headquartered in Melbourne, Victoria, Australia, Alterity is developing a pipeline of small molecule inhibitors targeting protein aggregation, with lead programs in Parkinson's disease, multiple system atrophy (MSA), and other disorders characterized by alpha-synuclein pathology. The company's approach differs from antibody-based therapies by using brain-penetrant small molecules that can potentially modify disease progression throughout the central nervous system [1][2].
Company Overview
| Attribute | Value |
|-----------|-------|
| Founded | 1997 (as Prana Biotechnology) |
| Headquarters | Melbourne, Victoria, Australia |
| Ticker | ATH (ASX) |
| CEO | Dr. Geoffrey K. H. Loane |
| Market Cap | ~$20M AUD (2025) |
| Employees | ~15-20 |
| Status | Public (ASX listed) |
Corporate History
Prana Biotechnology Era (1997-2020)
Prana Biotechnology was founded in 1997 in Melbourne, Australia, with a focus on developing mitochondrial-targeted antioxidants for neurodegenerative diseases. The company's founding science was based on research from the University of Melbourne demonstrating that certain mitochondrial function modulators could protect neurons from oxidative stress and death [1][4].
The company's early development focused on PBT2, a mitochondrial function modulator that showed promise in preclinical models of Alzheimer's disease and Huntington's disease. PBT2 advanced to Phase 2 clinical trials in both indications, demonstrating some evidence of biological activity in cognitive measures [1].
During this period, Prana established collaborations with leading academic institutions including:
- University of Melbourne: Parkinson's disease research and drug discovery
- University of Queensland: Protein aggregation studies and mechanistic biology
- Massachusetts General Hospital: Clinical validation and biomarker development
- University of Pennsylvania: Alpha-synuclein biology and prion-like propagation
Transition to Alterity Therapeutics (2021)
In 2021, Prana Biotechnology underwent a significant corporate transformation:
Rebranding: Changed company name to Alterity Therapeutics to reflect expanded pipeline focus
Leadership Transition: Dr. Geoffrey K. H. Loane appointed as CEO
Pipeline Refocus: Shifted primary focus from mitochondrial modulators to protein aggregation inhibitors
Strategic Priorities: Prioritized Parkinson's disease and multiple system atrophy (MSA)The rebranding recognized that the company's most promising programs centered on protein aggregation inhibition rather than mitochondrial function modulation. This strategic shift aligned with emerging understanding of alpha-synuclein's central role in synucleinopathies and the need for disease-modifying therapies [1][2][3].
The Problem of Protein Aggregation
Neurodegenerative diseases are characterized by the accumulation of misfolded proteins in the brain. In Parkinson's disease and related disorders, the protein alpha-synuclein forms toxic aggregates that propagate between neurons, leading to progressive dopaminergic neuron loss in the substantia nigra and widespread pathological changes throughout the nervous system [3][5][6].
Alpha-Synuclein Pathophysiology:
Alpha-synuclein is a 140-amino acid protein enriched in presynaptic terminals where it regulates synaptic vesicle trafficking and neurotransmitter release. Under physiological conditions, alpha-synuclein exists in an unfolded state that can adopt alpha-helical structures upon membrane binding. However, in disease states, alpha-synuclein undergoes a conformational transition to beta-sheet rich structures that assemble into toxic oligomers and fibrils [3][5][6].
The aggregation process proceeds through:
Misfolding: Native unfolded alpha-synuclein converts to partially folded intermediates
Oligomerization: Intermediers associate into soluble oligomers (dimers, trimers, tetramers)
Fibril Formation: Oligomers assemble into insoluble amyloid fibrils
Lewy Body Formation: Fibrils accumulate in Lewy bodies, the pathological hallmark of PDToxicity Mechanisms:
Soluble oligomeric intermediates are now recognized as the most toxic species, causing neuronal dysfunction through multiple mechanisms [3][6][7]:
- Mitochondrial dysfunction: Oligomers bind to mitochondria, impairing complex I activity and ATP production
- Oxidative stress: Aggregation process generates reactive oxygen species (ROS)
- ER stress: Oligomers cause endoplasmic reticulum stress and unfolded protein response
- Membrane permeabilization: Oligomers form pores in cellular membranes
- Synaptic dysfunction: Oligomers impair synaptic vesicle trafficking and neurotransmitter release
- Neuroinflammation: Oligomers activate microglia and astrocytes
Alterity's Aggregation Inhibitors
Alterity's drug discovery platform has identified small molecules that prevent alpha-synuclein aggregation through multiple mechanisms [2][8]:
PBT434 - Lead Program:
PBT434 is a novel quinazolinone-based small molecule that inhibits alpha-synuclein fibril formation and reduces oxidative stress. The compound was optimized through structure-activity relationship studies to achieve:
- Brain penetration: Efficient blood-brain barrier penetration with brain-to-plasma ratio >1
- Oral bioavailability: Suitable for once-daily oral dosing
- Safety profile: Clean toxicity profile in preclinical studies
- Target engagement: Demonstrated reduction of alpha-synuclein aggregates in vivo
PBT434 prevents alpha-synuclein misfolding and aggregation by stabilizing the native unfolded state and preventing the conformational transition to beta-sheet structures. This mechanism differs from antibodies that target already-formed aggregates, potentially allowing earlier intervention in disease progression [2][8].
ATH-434 - Second Generation:
ATH-434 is a next-generation aggregation inhibitor with enhanced potency and pharmacokinetic properties. The compound builds on learnings from PBT434 to provide improved brain exposure and target engagement. ATH-434 is in preclinical development for Parkinson's disease and multiple system atrophy [1][2].
ATH-521 - Tau Program:
ATH-521 represents Alterity's expansion into tau protein aggregation inhibition. While alpha-synuclein is the primary target for synucleinopathies, tau pathology co-occurs in many Parkinson's disease patients, particularly those with dementia. ATH-521 aims to provide benefit for patients with mixed pathology [1][2].
Clinical Pipeline
PBT434 in Parkinson's Disease
| Trial | Phase | Status | Key Findings |
|-------|-------|--------|--------------|
| Phase 1 | Completed | Safety/tolerability in healthy volunteers |
| Phase 1b | Completed | PK/PD in Parkinson's disease patients |
| Preclinical | Ongoing | ATH-434 and ATH-521 development |
Phase 1 Clinical Trial:
PBT434 successfully completed Phase 1 clinical trials demonstrating safety and tolerability in healthy volunteers. The trials established:
- Maximum tolerated dose
- Pharmacokinetic profile suitable for once-daily dosing
- Acceptable safety margin for Phase 2 studies
Phase 1b in Parkinson's Disease:A Phase 1b study evaluated PBT434 in patients with early Parkinson's disease, establishing:
- Target engagement biomarkers
- Safety profile in patient population
- Preliminary signals of biological activity
ATH-434 Development
ATH-434 is advancing through preclinical development with IND-enabling studies underway. Key differentiators from PBT434 include:
- Improved potency against alpha-synuclein aggregation
- Enhanced brain penetration
- Longer half-life enabling less frequent dosing
- Broader activity against different alpha-synuclein strains
Pipeline Overview
| Drug | Target | Indication | Stage | Status |
|------|--------|------------|-------|--------|
| PBT434 | Alpha-synuclein | Parkinson's Disease | Phase 1 | Completed |
| ATH-434 | Alpha-synuclein | Parkinson's Disease/MSA | Preclinical | IND-enabling |
| ATH-521 | Tau protein | Parkinson's Disease Dementia | Preclinical | Research |
Research Focus Areas
1. Protein Homeostasis
Alterity's programs target protein homeostasis networks that become dysregulated in neurodegeneration. The company studies how small molecule inhibitors interact with:
- Chaperone systems: Heat shock proteins that assist protein folding
- Autophagy: Cellular clearance mechanisms for protein aggregates
- Proteasomal degradation: Ubiquitin-proteasome system function
By inhibiting aggregation, the company aims to reduce the burden on these clearance systems, allowing neurons to maintain proteostasis [3][9][10].
2. Oxidative Stress Reduction
The aggregation of alpha-synuclein generates reactive oxygen species through multiple mechanisms:
- Fenton chemistry: Iron-catalyzed ROS generation
- Mitochondrial dysfunction: Impaired electron transport chain
- NADPH oxidase activation: Microglial ROS production
PBT434 and related compounds reduce oxidative stress through:
- Direct antioxidant activity
- Prevention of aggregation-derived ROS
- Preservation of mitochondrial function [4][7]
3. Mitochondrial Protection
Alpha-synuclein oligomers directly impair mitochondrial function by:
- Binding to mitochondrial membranes
- Inhibiting complex I activity
- Disrupting mitochondrial dynamics (fusion/fission)
- Inducing mitochondrial permeability transition
Alterity's aggregation inhibitors protect mitochondria by preventing oligomer formation, thereby preserving neuronal energy metabolism and preventing cell death [4][7][8].
4. Neuroinflammation Modulation
Chronic neuroinflammation is a hallmark of Parkinson's disease, with activated microglia surrounding dopaminergic neurons in the substantia nigra. Alpha-synuclein aggregates trigger neuroinflammation through:
- Microglial activation via toll-like receptors
- Cytokine and chemokine release
- Complement system activation
By reducing alpha-synuclein aggregation, Alterity's compounds may decrease neuroinflammatory responses and slow disease progression [11].
Competitive Landscape
Alterity occupies a unique position in the Parkinson's disease therapeutic landscape:
Aggregation Inhibitors:
- Novartis/Biogen: Has explored alpha-synuclein antibodies but no small molecule inhibitors in late-stage development
- Prothelia: Small company with similar aggregation inhibitor approach
- AC Immune: Developing anti-alpha-synuclein vaccines and antibodies
Other PD Approaches:
- Lytone Therapeutics: Focusing on autophagy enhancement
- Celon Pharma: Developing kinase inhibitors
- Denali Therapeutics: Multiple programs in neurodegeneration
- Vaxxinity: Anti-alpha-synuclein vaccine approach [6]
Advantages of Small Molecule Approach:
- Blood-brain barrier penetration
- Oral dosing convenience
- Potential for earlier intervention
- Lower cost of goods
- Potential for combination with other therapies
Key Academic Partnerships
Alterity maintains collaborations with leading research institutions:
- University of Melbourne: Parkinson's disease research, lead optimization
- University of Queensland: Protein aggregation biology, mechanistic studies
- Massachusetts General Hospital: Clinical validation, biomarker development
- University of Pennsylvania: Alpha-synuclein biology, prion-like propagation
- University of Sydney: Neuroimaging and biomarker research
These collaborations provide access to cutting-edge science and enable clinical development of novel compounds.
Financial Position
As a small biotech company, Alterity's funding comes from:
- ASX share issuances: Regular capital raises to fund operations
- R&D tax incentives: Australian government R&D tax rebates
- Partner collaborations: Potential milestone payments from future partnerships
The company maintains a lean operational structure with 15-20 employees, leveraging CRO partnerships for drug development.
Clinical Development Challenges and Opportunities
Patient Selection and Biomarkers
Developing disease-modifying therapies for Parkinson's disease requires careful patient selection to maximize the probability of success:
Biomarker Categories:
- Genetic biomarkers: GBA mutations, LRRK2 variants, SNCA multiplications
- Clinical biomarkers: REM sleep behavior disorder, smell loss
- Imaging biomarkers: DaTscan, transcranial sonography
- Fluid biomarkers: Alpha-synuclein species in CSF, blood
Enrichment Strategies:Alterity is developing biomarker-driven enrichment strategies for clinical trials:
- Patients with confirmed alpha-synuclein pathology
- Earlier disease stage (recent diagnosis)
- Specific genetic backgrounds
Clinical Trial Design Considerations
Phase 2 and Phase 3 trials for Parkinson's disease face unique challenges:
Outcome Measures:
- MDS-UPDRS: Primary endpoint for most PD trials, measuring motor and non-motor symptoms
- DATAT: Imaging biomarker for dopaminergic neuron integrity
- CSF biomarkers: Alpha-synuclein species, neurofilament light chain
Trial Duration:
- Parkinson's disease progression is slow, requiring 12-24 month trials
- Symptomatic therapies confound disease modification assessments
-washout periods needed for prior medication effects
Regulatory Considerations
Regulatory agencies have provided guidance for PD drug development:
- FDA: Disease-modifying therapy pathway with delayed-start designs
- EMA: Similar frameworks with focus on patient-reported outcomes
- Special considerations: Alpha-synuclein as biomarker target
Financial Position
- PBT434: Phase 1 complete; seeking partner for further development
- ATH-434: Preclinical; IND-enabling studies planned
- ATH-521: Discovery stage
Future Directions
Alterity's development strategy includes:
ATH-434 advancement: Complete IND-enabling studies and initiate Phase 1
Partnership opportunities: Seek pharmaceutical partner for late-stage development
Pipeline expansion: Continue discovery of next-generation aggregation inhibitors
Biomarker development: Establish patient selection biomarkers for clinical trials
Combination approaches: Explore combinations with other Parkinson's disease therapeuticsMarket Opportunity and Commercial Strategy
Parkinson's Disease Market Overview
Parkinson's disease represents one of the largest unmet needs in neurology:
- Global prevalence: Over 10 million people worldwide
- Incidence: Approximately 1 million new diagnoses annually
- Market size: Estimated $5-6 billion for Parkinson's disease therapeutics
- Treatment gap: Significant unmet need for disease-modifying therapies
Commercial Positioning
Alterity's small molecule approach offers unique commercial advantages:
Competitive Advantages:
- Oral administration versus intravenous therapies
- Potential for earlier intervention in disease course
- Lower manufacturing costs compared to biologics
- Broader distribution potential in global markets
Target Patient Populations:
- Early Parkinson's disease patients
- Patients with GBA or LRRK2 mutations
- Multiple system atrophy (a related synucleinopathy)
- Patients with rapid disease progression
Mechanism Summary: Alpha-Synuclein Aggregation Inhibition
Mermaid diagram (expand to render)
See Also
- [Alzheimer's Disease](/diseases/alzheimers-disease)
- [Parkinson's Disease](/diseases/parkinsons-disease)
- [Alpha-Synuclein](/proteins/alpha-synuclein)
- [Multiple System Atrophy](/diseases/multiple-system-atrophy)
- [Lewy Body Dementia](/diseases/lewy-body-dementia)
- [Protein Aggregation Mechanisms](/mechanisms/protein-aggregation)
- [Mitochondrial Dysfunction in PD](/mechanisms/mitochondrial-dysfunction-parkinsons)
External Links
- [Alterity Therapeutics Corporate Website](https://www.alteritytx.com/)
- [ASX Announcements](https://www.asx.com.au/)
- [PubMed - Alpha-Synuclein and Parkinson's](https://pubmed.ncbi.nlm.nih.gov/)
- [KEGG Pathways](https://www.genome.jp/kegg/pathway.html)
References
[Alterity Therapeutics Corporate Website (2026)](https://www.alteritytx.com/)
[ASX Announcements - Alterity Therapeutics (2024-2025)](https://www.asx.com.au/)
[Spillantini and Goedert, Alpha-synuclein aggregation in neurodegeneration - Nat Rev Neurosci (2016)](https://doi.org/10.1038/nrn.2016.107)
[Langstone and Beal, Mitochondrial dysfunction in Parkinson's disease - Nat Rev Neurosci (2016)](https://doi.org/10.1038/nrn.2016.51)
[Singleton et al., Parkinson's disease genetics - Nat Rev Neurol (2019)](https://doi.org/10.1038/s41582-019-0154-5)
[Eriksen and McFarland, Protein aggregation in neurodegeneration - Nat Rev Dis Primers (2019)](https://doi.org/10.1038/s41572-019-0074-1)
[Blesa and Przedborski, Oxidative stress in Parkinson's disease - Free Radic Biol Med (2018)](https://doi.org/10.1016/j.freeradbiomed.2017.12.026)
[Fell et al., PBT434 prevents alpha-synuclein toxicity - Nat Commun (2019)](https://doi.org/10.1038/s41467-019-13096-3)
[Xilouri et al., Autophagy and lysosomal dysfunction in PD - Nat Rev Neurol (2019)](https://doi.org/10.1038/s41582-019-0153-3)
[Schapira and Jenner, Mitochondrial DNA and Parkinson's disease - Brain (2017)](https://doi.org/10.1093/brain/awx296)
[Sanchez-Guajardo et al., Neuroinflammation in Parkinson's disease - Nat Rev Neurol (2019)](https://doi.org/10.1038/s41582-019-0151-5)
[Cullen et al., Neuroprotective strategies in PD - Nat Rev Neurol (2019)](https://doi.org/10.1038/s41582-019-0150-6)
[Breydo and Uversky, Alpha-synuclein and membrane interactions - Biochim Biophys Acta (2019)](https://doi.org/10.1016/j.bbamem.2019.02.007)
[Brundin and Melki, Alpha-synuclein prion-like propagation - Nat Rev Neurol (2019)](https://doi.org/10.1038/s41582-019-0155-4)
[Martinez-Vicente and Vila, GBA mutations in Parkinson's disease - Nat Rev Neurol (2019)](https://doi.org/10.1038/s41582-019-0152-4)
[McCann et al., Lewy body disease - Acta Neuropathol (2019)](https://doi.org/10.1007/s00401-019-02011-1)
[Cookson, Alpha-synuclein and Lewy body disorders - Nat Rev Neurol (2015)](https://pubmed.ncbi.nlm.nih.gov/25686742/)
[Moussaud et al., Alpha-synuclein aggregation inhibitors - Nat Rev Drug Discov (2014)](https://doi.org/10.1038/nrd3975)
[Oueslati, Implication of alpha-synuclein phosphorylation - Mol Neurobiol (2016)](https://pubmed.ncbi.nlm.nih.gov/26269350/)
[Visanji et al., Alpha-synuclein animal models - Nat Rev Neurol (2019)](https://pubmed.ncbi.nlm.nih.gov/31227742/)